BioMedNewsBreaks

ThursdayApr 21, 2022 1:15 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived from psilocybin, Cybin’s CYB003 is part of a family of molecules called indolamines that include common neurotransmitters such as serotonin. The molecule will be the first psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). According to…

Continue Reading

ThursdayApr 21, 2022 11:59 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Expansion of Rare Cannabinoid Portfolio

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is launching business-to-business sales of its rare cannabinoid cannabidivarin (“CBDV”). Through subsidiary BayMedica LLC, InMed will offer its product to wholesalers, suppliers and end-product manufacturers in the health and wellness sector. In addition, the company released a white paper focused on research into the therapeutic potential of CBDV. According to the announcement, CBDV is a nonintoxicating rare cannabinoid that is similar to CBD but offers important differences in activity. One of the most-studied rare cannabinoids, CBDV is currently the focus of several different clinical…

Continue Reading

WednesdayApr 20, 2022 11:48 am

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Produces First Batch of SPU-21 Liposomes for RA Study

Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. The company today announced that it has produced its first batch of liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). According to the update, the ability of the SPU-21 to target inflamed epithelium suggest their potential use to target drug delivery. Silo’s novel joint homing peptides can be used to treat autoimmune diseases, which include but are not limited to rheumatoid arthritis (“RA”). This approach could enhance the therapeutic effect of…

Continue Reading

TuesdayApr 19, 2022 12:31 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Conferences

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will be involved in several conferences in April and May. Company management will be participating at the Benzinga Spring Cannabis Capital Conference, scheduled for April 20–21, 2022, in Miami Beach, Florida. InMed executives will be meeting virtually with institutions and industry representatives. Company executives will also be at Canaccord Genuity’s sixth annual Global Cannabis Conference held on May 11, 2022. A recording of the company’s presentation will be available on InMed’s investor relations website following the event. Company leaders will also be available for…

Continue Reading

MondayApr 18, 2022 2:35 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the…

Continue Reading

ThursdayApr 14, 2022 9:33 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), was spotlighted in an episode of the Power Play by the Market Herald. Cybin CEO Doug Drysdale talked with host Dave Jackson about the company’s recent positive results from its CYB004 pharmacokinetic study. The company announced that the study produced positive preclinical data demonstrating that when inhaled, Cybin’s deuterated dimethyltryptamine (“DMT”) molecule indicated advantages, such as a longer duration of action and improved bioavailability, over both IV DMT and inhaled DMT. Power Play interviews with company executives offer investors a quick snapshot of an array of…

Continue Reading

WednesdayApr 13, 2022 11:33 am

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side…

Continue Reading

TuesdayApr 12, 2022 2:39 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New Director, CEO

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced that its board of directors has nominated Dr. David R. Richards, PhD, FIoD, FRSA, CPsych, as a new director and the company’s chief executive officer. Richards comes to the new positions with impressive experience, including serving in leadership roles at Nortel Networks' GM Global Data; GM Global Supercarriers; GM UK Switching; and Global ThinkQuest Champion at Oracle's Education Foundation. He has served as CEO of Ellis Jones Solicitors, executive director of…

Continue Reading

TuesdayApr 12, 2022 12:27 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John Climaco, along with opinion leader Samuel A. Goldlust, MD. The focus of the chat will be GBM and the work that CNS Pharmaceuticals is doing to advance Berubicin, its novel anthracycline and the first anthracycline to…

Continue Reading

FridayApr 08, 2022 1:29 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with mental health and addiction disorders with unmet needs,” the article reads. “Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment…

Continue Reading